Monitor the conference for any incremental commentary on Phase 3 trial design or timelines, but this filing alone provides no catalyst. The next material catalyst remains the initiation of the Phase 3 trial for ATH434.
Price Chart
Executive Summary
Alterity Therapeutics filed a 6-K announcing that CEO David Stamler will present at the Canaccord Genuity Drug and Device Conference on October 12, 2026. The presentation is a routine corporate update with no new clinical data, financial results, or material disclosures beyond previously announced plans to initiate a Phase 3 trial for ATH434 in Multiple System Atrophy.
Key Facts
- CEO David Stamler will present at the Canaccord Genuity Drug and Device Conference on October 12, 2026 at 3:50 p.m. AEST.
- The presentation includes a corporate overview and roundtable discussions with investors.
- No new clinical data, financial results, or material business developments were disclosed.
- The company is preparing to initiate a Phase 3 pivotal trial for ATH434 in Multiple System Atrophy, as previously disclosed.
Financial Impact
No financial impact — routine conference participation with no new material information.
Risk Factors
- No new data or catalysts were announced, so the stock may continue its recent negative drift.
- The company faces going-concern risk as noted in the prior 20-F, requiring further capital raises.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001437749-26-032387 |
| Exhibit: ex_1024289.htm | 0001437749-26-032387 |
| Document: 0001437749-26-032387-index-headers.html | 0001437749-26-032387 |
| Document: 0001437749-26-032387-index.html | 0001437749-26-032387 |
| Document: 0001437749-26-032387.txt | 0001437749-26-032387 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 4d ago | 6-K | $2.09 | awaiting T+60 | — | $2.08 (+0.48%) |
Oct 23, 2026 4d ago | 6-K | $2.09 | awaiting T+60 | — | $2.08 (−0.48%) |
Oct 23, 2026 4d ago | 6-K | $2.09 | awaiting T+60 | — | $2.08 (−0.48%) |
Oct 21, 2026 6d ago | 6-K | $2.39 | awaiting T+60 | — | $2.08 (−12.97%) |
Oct 21, 2026 6d ago | 6-K | $2.39 | awaiting T+60 | — | $2.08 (−12.97%) |
Oct 19, 2026 8d ago | 6-K | $2.43 | awaiting T+60 | — | $2.08 (−14.40%) |
Oct 9, 2026 18d ago | 6-K | $3.12 | awaiting T+60 | — | $2.08 (−33.33%) |
Oct 5, 2026 22d ago | Press Release | $3.22 | awaiting T+60 | — | $2.08 (−35.40%) |
Oct 5, 2026 22d ago | 6-K | $3.22 | awaiting T+60 | — | $2.08 (−35.40%) |
Sep 25, 2026 4w ago | 6-K | $3.67 | awaiting T+60 | — | $2.08 (−43.32%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers